lisata therapeutics inc - LSTA
LSTA
Close Chg Chg %
1.86 -0.05 -2.71%
Open Market
1.81
-0.05 (2.71%)
Volume: 55.28K
Last Updated:
Sep 9, 2026, 11:10 AM EDT
Company Overview: lisata therapeutics inc - LSTA
LSTA Key Data
| Open $1.86 | Day Range 1.73 - 1.88 |
| 52 Week Range 0.99 - 5.06 | Market Cap $14.87M |
| Shares Outstanding 9.01M | Public Float 6.87M |
| Beta 0.95 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.64 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 509.61K |
LSTA Performance
| 1 Week | 0.00% | ||
| 1 Month | 55.66% | ||
| 3 Months | -53.65% | ||
| 1 Year | -24.66% | ||
| 5 Years | -91.13% |
LSTA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About lisata therapeutics inc - LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.
LSTA At a Glance
Lisata Therapeutics, Inc.
110 Allen Road
Basking Ridge, New Jersey 07920
| Phone | 1-908-842-0100 | Revenue | 170.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -16,586,000.00 | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LSTA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 95.046 |
| Price to Book Ratio | 1.106 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.003 |
| Enterprise Value to Sales | -0.307 |
| Total Debt to Enterprise Value | N/A |
LSTA Efficiency
| Revenue/Employee | 8,095.238 |
| Income Per Employee | -789,809.524 |
| Receivables Turnover | 0.243 |
| Total Asset Turnover | 0.006 |
LSTA Liquidity
| Current Ratio | 5.765 |
| Quick Ratio | 5.765 |
| Cash Ratio | 5.196 |
LSTA Profitability
| Gross Margin | 14.118 |
| Operating Margin | -10,711.176 |
| Pretax Margin | -10,322.353 |
| Net Margin | -9,756.471 |
| Return on Assets | -62.89 |
| Return on Equity | -74.668 |
| Return on Total Capital | -111.653 |
| Return on Invested Capital | -74.668 |
LSTA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Lisata Therapeutics Inc - LSTA
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 1.00M | 170.00K | - |
Sales Growth
| - | - | - | -83.00% | - |
Cost of Goods Sold (COGS) incl D&A
| 69.00K | 189.00K | 174.00K | 146.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 69.00K | 189.00K | 174.00K | 146.00K | |
Depreciation
| 48.00K | 118.00K | 103.00K | 81.00K | |
Amortization of Intangibles
| 21.00K | 71.00K | 71.00K | 65.00K | |
COGS Growth
| +25.45% | +173.91% | -7.94% | -16.09% | |
Gross Income
| (69.00K) | (189.00K) | 826.00K | 24.00K | |
Gross Income Growth
| -25.45% | -173.91% | +537.04% | -97.09% | |
Gross Profit Margin
| - | - | +82.60% | +14.12% | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 27.14M | 25.52M | 23.23M | 18.23M | |
Research & Development
| 13.07M | 12.73M | 11.33M | 7.95M | |
Other SG&A
| 14.07M | 12.79M | 11.90M | 10.28M | |
SGA Growth
| -6.40% | -5.97% | -8.95% | -21.53% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 30.39M | - |
EBIT after Unusual Expense
| (57.60M) | (25.71M) | (22.41M) | (18.21M) | |
Non Operating Income/Expense
| 897.00K | 2.54M | 1.63M | 661.00K | |
Non-Operating Interest Income
| 1.05M | 2.72M | 1.88M | 806.00K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (56.70M) | (23.17M) | (20.78M) | (17.55M) | |
Pretax Income Growth
| -95.71% | +59.14% | +10.30% | +15.57% | |
Pretax Margin
| - | - | -2,078.30% | -10,322.35% | - |
Income Tax
| (2.48M) | (2.33M) | (798.00K) | (962.00K) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (2.48M) | (2.33M) | (798.00K) | (962.00K) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (54.23M) | (20.84M) | (19.98M) | (16.59M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (54.23M) | (20.84M) | (19.98M) | (16.59M) | |
Net Income Growth
| -97.43% | +61.57% | +4.10% | +17.01% | |
Net Margin Growth
| - | - | -1,998.50% | -9,756.47% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (54.23M) | (20.84M) | (19.98M) | (16.59M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (54.23M) | (20.84M) | (19.98M) | (16.59M) | |
EPS (Basic)
| -10.4682 | -2.5814 | -2.3994 | -1.9093 | |
EPS (Basic) Growth
| -40.54% | +75.34% | +7.05% | +20.43% | |
Basic Shares Outstanding
| 5.18M | 8.07M | 8.33M | 8.69M | |
EPS (Diluted)
| -10.4682 | -2.5814 | -2.3994 | -1.9093 | |
EPS (Diluted) Growth
| -40.54% | +75.34% | +7.05% | +20.43% | |
Diluted Shares Outstanding
| 5.18M | 8.07M | 8.33M | 8.69M | |
EBITDA
| (27.14M) | (25.52M) | (22.23M) | (18.06M) | |
EBITDA Growth
| +6.40% | +5.97% | +12.87% | +18.76% | |
EBITDA Margin
| - | - | -2,223.50% | -10,625.29% | - |
An error occurred while fetching the data.
SEC Filings for Lisata Therapeutics Inc - LSTA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Lisata Therapeutics Inc - LSTA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 14, 2026 | Cynthia L. Flowers Director | 95,446 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Tariq Imam SVP, Bus Dev, General Counsel | 7,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | James Nisco SVP, Fin/Treas, Chief Actg Off | 34,229 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 67,431.13 |
| Jan 14, 2026 | James Nisco SVP, Fin/Treas, Chief Actg Off | 36,360 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 71,629.20 |
| Jan 14, 2026 | James Nisco SVP, Fin/Treas, Chief Actg Off | 38,491 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Kristen K. Buck EVP, R&D and CMO | 13,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Kristen K. Buck EVP, R&D and CMO | 93,462 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 184,120.14 |
| Jan 14, 2026 | Kristen K. Buck EVP, R&D and CMO | 95,609 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 188,349.73 |
| Jan 14, 2026 | Kristen K. Buck EVP, R&D and CMO | 98,830 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 194,695.10 |
| Jan 14, 2026 | Kristen K. Buck EVP, R&D and CMO | 101,812 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 200,569.64 |
| Jan 14, 2026 | Kristen K. Buck EVP, R&D and CMO | 104,794 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Heidi Henson Director | 85,725 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | David J. Mazzo President & CEO; Director | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | David J. Mazzo President & CEO; Director | 311,890 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 614,423.30 |
| Jan 14, 2026 | David J. Mazzo President & CEO; Director | 319,744 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 629,895.68 |
| Jan 14, 2026 | David J. Mazzo President & CEO; Director | 331,968 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 653,976.96 |
| Jan 14, 2026 | David J. Mazzo President & CEO; Director | 342,483 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.97 per share | 674,691.51 |
| Jan 14, 2026 | David J. Mazzo President & CEO; Director | 352,986 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Gregory B. Brown Director | 95,659 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Mohammad Magdy Mohamed Azab Director | 104,925 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |